These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36574856)

  • 1. Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway.
    Ying Z; van Eenige R; Beerepoot R; Boon MR; Kloosterhuis NJ; van de Sluis B; Bartelt A; Rensen PCN; Kooijman S
    Pharmacol Res; 2023 Jan; 187():106634. PubMed ID: 36574856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Hoeke G; Wang Y; van Dam AD; Mol IM; Gart E; Klop HG; van den Berg SM; Pieterman EH; Princen HMG; Groen AK; Rensen PCN; Berbée JFP; Boon MR
    Atherosclerosis; 2017 Dec; 267():116-126. PubMed ID: 29121499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development.
    Berbée JF; Boon MR; Khedoe PP; Bartelt A; Schlein C; Worthmann A; Kooijman S; Hoeke G; Mol IM; John C; Jung C; Vazirpanah N; Brouwers LP; Gordts PL; Esko JD; Hiemstra PS; Havekes LM; Scheja L; Heeren J; Rensen PC
    Nat Commun; 2015 Mar; 6():6356. PubMed ID: 25754609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis.
    Sui W; Li H; Yang Y; Jing X; Xue F; Cheng J; Dong M; Zhang M; Pan H; Chen Y; Zhang Y; Zhou Q; Shi W; Wang X; Zhang H; Zhang C; Zhang Y; Cao Y
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10937-10942. PubMed ID: 31085638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
    Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
    Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.
    Liu C; Schönke M; Zhou E; Li Z; Kooijman S; Boon MR; Larsson M; Wallenius K; Dekker N; Barlind L; Peng XR; Wang Y; Rensen PCN
    Cardiovasc Res; 2022 Jan; 118(2):489-502. PubMed ID: 33693480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary choline increases brown adipose tissue activation markers and improves cholesterol metabolism in female APOE*3-Leiden.CETP mice.
    Liu C; Song Z; Li Z; Boon MR; Schönke M; Rensen PCN; Wang Y
    Int J Obes (Lond); 2023 Mar; 47(3):236-243. PubMed ID: 36732416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aging attenuates diurnal lipid uptake by brown adipose tissue.
    In Het Panhuis W; Schönke M; Siebeler R; Afkir S; Baelde R; Pronk ACM; Streefland TCM; Sips HCM; Lalai RA; Rensen PCN; Kooijman S
    Aging (Albany NY); 2022 Oct; 14(19):7734-7751. PubMed ID: 36202134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans.
    Ying Z; Tramper N; Zhou E; Boon MR; Rensen PCN; Kooijman S
    Cardiovasc Res; 2023 May; 119(4):905-918. PubMed ID: 35944189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Brown Fat in Lipoprotein Metabolism and Atherosclerosis.
    Hoeke G; Kooijman S; Boon MR; Rensen PC; Berbée JF
    Circ Res; 2016 Jan; 118(1):173-82. PubMed ID: 26837747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice.
    Wang S; Miller B; Matthan NR; Goktas Z; Wu D; Reed DB; Yin X; Grammas P; Moustaid-Moussa N; Shen CL; Lichtenstein AH
    Nutr Res; 2013 Dec; 33(12):1072-82. PubMed ID: 24267047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice.
    Geerling JJ; Boon MR; van der Zon GC; van den Berg SA; van den Hoek AM; Lombès M; Princen HM; Havekes LM; Rensen PC; Guigas B
    Diabetes; 2014 Mar; 63(3):880-91. PubMed ID: 24270984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development.
    Zhou E; Hoeke G; Li Z; Eibergen AC; Schonk AW; Koehorst M; Boverhof R; Havinga R; Kuipers F; Coskun T; Boon MR; Groen AK; Rensen PCN; Berbée JFP; Wang Y
    Cardiovasc Res; 2020 Aug; 116(10):1710-1720. PubMed ID: 31589318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hepatic Surf4 in lipoprotein metabolism and the development of atherosclerosis in apoE
    Shen Y; Gu HM; Zhai L; Wang B; Qin S; Zhang DW
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Oct; 1867(10):159196. PubMed ID: 35803528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE.
    van Dijk KW; van Vlijmen BJ; van't Hof HB; van der Zee A; Santamarina-Fojo S; van Berkel TJ; Havekes LM; Hofker MH
    J Lipid Res; 1999 Feb; 40(2):336-44. PubMed ID: 9925664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.